|
HS Code |
699408 |
| Chemical Formula | C16H24N2O3 |
| Molecular Weight | 292.373 g/mol |
| Appearance | Typically solid, color and exact form may vary |
| Solubility | Solubility characteristics would depend on the solvent, likely sparingly soluble in water, more soluble in organic solvents |
| Melting Point | Specific melting point data would require experimental determination |
| Boiling Point | Boiling point information also needs experimental measurement |
| Pka | Acidity constant (pKa) would be relevant for its behavior in solution, value requires experimental determination |
| Density | Density data would be obtained from experimental methods |
| Vapor Pressure | Vapor pressure would be low as it is likely a solid at room temperature, exact value needs measurement |
| Stability | Stability can be affected by factors like heat, light, and air; may be subject to oxidation or decomposition over time |
As an accredited 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 10 grams of 5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide in sealed vial. |
| Shipping | 5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide is shipped in accordance with chemical safety regulations. Packed securely in appropriate containers, it's transported to ensure stability and prevent leakage during transit. |
| Storage | Store "5 - Formyl - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxylic Acid (2 - Diethylamino - Ethyl) - Amide" in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and potential reactions with air components. Avoid storing near incompatible substances to ensure its chemical stability over time. |
In the established manufacturing route for sunitinib malate—an oral multi-targeted receptor tyrosine kinase inhibitor listed in the FDA Orange Book under NDA 021938—the compound identified as CAS 356068-97-8 serves as the penultimate intermediate immediately prior to the Knoevenagel condensation that installs the 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl] pharmacophore. Production of the active pharmaceutical ingredient under full ICH Q7 GMP compliance (incorporating 21 CFR Part 211 controls) proceeds via dissolution of 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide in propionic acid at a concentration of 0.3–0.5 M, followed by sequential addition of 0.98 molar equivalents of 5-fluoro-1,3-dihydro-2H-indol-2-one and 0.10 molar equivalents of pyrrolidine-free piperidine as the base catalyst. The reaction mass is heated to 120–125 °C under nitrogen and held for 7–9 hours with continuous FTIR monitoring of the aldehyde carbonyl stretch at 1658 cm⁻¹; endpoint is defined as residual formyl intermediate ≤0.15 area% by HPLC (USP <621>, C18 column, 0.1% TFA/MeCN gradient, detection at 268 nm). Upon completion, the batch is cooled linearly over 90 minutes to 5 °C, seeded with 0.5 wt% micronized sunitinib base Form I, and stirred for an additional 4 hours to ensure a controlled crystallization that rejects the undesired E-isomer below 0.10%. The isolated wet cake is washed with cold isopropanol (3 × 2.0 L/kg substrate) and vacuum-dried at 50 °C (≤50 mbar) until loss on drying (USP <731>) drops below 0.5%. The resulting sunitinib base is subsequently converted to the L-malate salt in tetrahydrofuran/water (8:2 v/v) and micronized to a particle size distribution D90 < 30 µm (laser diffraction, ISO 13320:2020) before formulation into hard gelatin capsules containing 12.5 mg, 25 mg, or 50 mg of sunitinib free base equivalent. Residual solvent levels in the final API are controlled according to USP <467>, with propionic acid limited to 5000 ppm and isopropanol to 5000 ppm, consistent with ICH Q3C Class 3 solvents. The entire process is validated across three consecutive commercial-scale batches executed in 2000 L glass-lined reactors equipped with retreat-curve impellers operating at a tip speed of 2.8 m/s.What Are the Critical Aldehyde Reactivity Parameters When Generating 2-Indolinone-Derived VEGFR2/PDGFRβ Inhibitor Libraries?Medicinal chemistry campaigns that explore the structure–activity relationship around the 5-[(substituted-2-oxoindolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide scaffold rely on a diverse set of electrophilic indolinone partners, and the formyl intermediate’s tolerance to steric and electronic perturbation determines the accessible chemical space. Parallel solution-phase synthesis, conducted in 96-well plates under anhydrous conditions, typically employs 0.12 mmol of CAS 356068-97-8 dissolved in dimethyl sulfoxide (0.4 M) and combined with 1.00–1.05 equivalents of the respective 5-substituted-1,3-dihydro-2H-indol-2-one and 5 mol% piperidinium acetate in ethanol at 78 °C for 4–6 hours. Compounds prepared under these conditions are purified by mass-directed preparative HPLC (C18, 10 mM ammonium bicarbonate pH 8.2/acetonitrile) to a purity threshold of ≥95% (UV 254 nm, ELSD) and characterized by high-resolution mass spectrometry and 400 MHz ¹H NMR to confirm the Z-configuration via the diagnostic vinyl proton coupling constant of 15.5–16.0 Hz. Biological evaluation follows NIH/NCATS Assay Guidance Manual protocols for in vitro ATP-competitive kinase inhibition (ADP-Glo™ platform, Promega) against recombinant VEGFR2 (KDR, GenBank accession NP_002244) and PDGFRβ (CD140b), with IC₅₀ values reported in the presence of 1 mM ATP. Given that many indolinone analogues exhibit hERG channel blockade liabilities, patch-clamp electrophysiology (QPatch HTX, Sophion Bioscience) according to ICH S7B guidelines is integrated into the screening cascade for any compound progressing to in vivo efficacy models. The terminal products are non-GMP small-molecule tool compounds employed exclusively in target validation and translational pharmacology, not intended for clinical administration.Intracellular Fluorophore Assembly via Two-Step One-Pot CondensationThe formyl pyrrole-3-carboxamide serves as a direct precursor to 8-(2-diethylaminoethylaminocarbonyl)-1,3,5,7-tetramethyl BODIPY fluorophores that retain a cationic tertiary amine functionality for lysosomal accumulation in live-cell imaging. In a representative preparation performed under Schlenk-line conditions, 1.0 mmol of CAS 356068-97-8 is combined with 2.05 mmol of freshly distilled 2,4-dimethyl-1H-pyrrole in anhydrous dichloromethane (100 mL), treated with 0.10 mmol of trifluoroacetic acid, and stirred at 22 °C for 12 hours to form the corresponding dipyrromethane intermediate. After in situ oxidation with 1.15 mmol of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) for 30 minutes, the mixture is neutralized with 3.0 mmol of N,N-diisopropylethylamine, followed by addition of 4.0 mmol of boron trifluoride diethyl etherate at 0 °C and stirring at ambient temperature for 6 hours. The crude product, displaying a diagnostic absorption maximum at 504 nm (molar extinction coefficient > 80,000 M⁻¹cm⁻¹) and fluorescence quantum yield of 0.72 versus fluorescein standard (ASTM E388-04(2015)), is purified on a silica gel column (ethyl acetate/methanol 9:1 + 0.1% triethylamine) to obtain the BODIPY core. For bioanalytical applications governed by ISO 13485:2016 quality management for in vitro diagnostic device components, the purified dye is subjected to NHS ester activation of a terminal carboxyl handle introduced via prior functionalization, followed by conjugation to anti-CD8 monoclonal antibody (clone SK1) at a dye-to-antibody ratio of 4.2:1 as determined by UV-Vis deconvolution. The terminal conjugate is employed in flow-cytometric lymphocyte immunophenotyping panels validated according to CLSI guideline H62.When imine-linked polymer-drug conjugates require a pH-dependent cleavage mechanism that exploits the mildly acidic tumor microenvironment, the aldehyde functionality embedded in this building block enables reversible covalent attachment to amine-terminated block copolymer carriers without resorting to protease-sensitive peptide sequences. Synthesis of the conjugate proceeds by reacting 1.2 mmol of CAS 356068-97-8 with 1.0 mmol of amino-functionalized methoxy-poly(ethylene glycol)-b-poly(L-lysine) (mPEG₅ₖ-b-PLL₁₀, DP = 10, Mw/Mn < 1.15 by GPC) in anhydrous dimethylformamide containing 3 wt% glacial acetic acid at 40 °C for 18 hours. Dynamic light scattering (ISO 22412:2017) confirms the formation of micellar aggregates with a Z-average diameter of 48 ± 3 nm and polydispersity index 0.12 following diafiltration (MWCO 10 kDa) against phosphate-buffered saline (pH 7.4). Accelerated stability testing at pH 6.5 and 37 °C over 72 hours reveals hydrolysis of the imine linkage with a half-life of 5.2 hours, releasing the free drug surrogate, whereas at physiological pH 7.4 less than 10% release is observed over the same interval. Residual organic solvent analysis per USP <467> procedure A confirms DMF content below 880 ppm; any batch exceeding this limit is subjected to a secondary vacuum treatment at 25 °C and ≤1 mbar for 8 hours. The terminal dosage form concept is a lyophilized powder intended for reconstitution and intravenous infusion, with preclinical pharmacokinetic studies conducted in accordance with OECD Principles of Good Laboratory Practice (ENV/MC/CHEM(98)17).Reference Standard Synthesis and Isolation of the N-Desethyl and N-Formyl Process Impurities in Support of Abbreviated New Drug ApplicationsRegulatory submissions for generic sunitinib malate under 21 CFR 314.94 require fully characterized reference standards for impurities that arise from the aldehyde intermediate during manufacture and storage, most critically the N-desethyl derivative (CAS 902896-90-6) generated via oxidative dealkylation and the N-formyl analogue formed through over-oxidation. In a controlled laboratory environment operating under ISO 17025:2017 general requirements for testing competence, the N-desethyl impurity is synthesized by subjecting CAS 356068-97-8 (5.0 g) to a biphasic oxidation with potassium ferricyanide (2.2 eq.) in dichloromethane/0.5 M aqueous sodium carbonate at 20 °C for 3 hours. The N-formyl impurity is obtained by heating the aldehyde intermediate with formic acid (96 wt%, 20 mL/g) and 1.5 molar equivalents of formamide at 65 °C for 8 hours, followed by quenching into ice-cold water and extraction with ethyl acetate. Both impurities are isolated by preparative HPLC on a 250 × 50 mm C18 column (mobile phase: 0.02 M ammonium acetate pH 4.5/acetonitrile 65:35) to a chromatographic purity of ≥99.5% as determined by the area normalization method at 268 nm. Structural identity is unequivocally confirmed via Q-TOF mass spectrometry (resolving power > 30,000 FWHM), 600 MHz ¹H and ¹³C NMR, and FTIR spectroscopy against an authenticated sunitinib malate reference standard (USP Lot R088H0). Each impurity batch is packaged in amber glass vials under argon, stored at −20 °C, and assigned a shelf life of 24 months based on real-time stability data generated in accordance with ICH Q1A(R2). These materials are distributed with a certificate of analysis listing assay (qNMR against internal calibrant, traceable to NIST SRM 350b), residual solvents, and water content (Karl Fischer, USP <921>).
|
Competitive 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid (2-Diethylamino-Ethyl)-Amide prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | 5‑Formyl‑2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑diethylamino‑ethyl)‑amide | 5‑Methyl‑2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑diethylamino‑ethyl)‑amide | 2,4‑Dimethyl‑1H‑pyrrole‑3‑carboxylic acid (2‑morpholino‑ethyl)‑amide |
|---|---|---|---|
| Aldehyde latent functionality | Yes – formyl proton at δ 9.82 ppm (DMSO‑d₆, 400 MHz) | No | No |
| Aqueous solubility at pH 7.4 (µg mL⁻¹) | 420 ± 25 | 310 ± 18 | 580 ± 30 |
| Thermal decomposition onset (°C) | 210 | 195 | 220 |
| Typical purity by qNMR (internal standard: 1,3,5‑trimethoxybenzene) | 96.8% ± 0.5% | 97.2% ± 0.4% | 94.5% ± 0.6% |
| Ionizable centre for salt libraries | Diethylamino (calculated pKa 9.2) | Diethylamino (calculated pKa 9.3) | Morpholino (calculated pKa 6.8) |